Autonomix Flags New Nasdaq MVLS Delisting Risk, Cash Runway to Q1 2027
AMIX has more than doubled off its 52-week low of $2.44 on light trading volume (0.1× avg).
Summary
Autonomix Medical's 10-Q reveals a new Nasdaq delisting risk from a $5M minimum market value rule and confirms cash runway only into Q1 2027, with $25-30M needed to reach commercialization.
Key Events · Earnings and Guidance · AMIX
-
New Nasdaq MVLS Delisting Risk
SEC approved a rule on July 22, 2026 requiring a $5M minimum Market Value of Listed Securities. If MVLS stays below $5M for 30 consecutive business days, Nasdaq issues a Staff Delisting Determination with immediate suspension and no cure period. The rule was automatically stayed on July 29, 2026 pending SEC review. Autonomix's market cap is approximately $7.3M, leaving little buffer above the threshold.
-
Cash Runway to Q1 2027
Cash of $3.5M as of June 30, 2026, plus $2.6M from the July 2026 warrant inducement, funds operations into but not beyond the first calendar quarter of 2027. Net cash used in operating activities was $3.5M for the quarter.
-
Financing Need Quantified
Management estimates requiring an additional $25-30 million to fund operations to commercialization of its first indication. No assurance that additional financing will be available on acceptable terms.
-
Going Concern Warning Reiterated
Substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued. Accumulated deficit of $69.8M and no revenues.
Analysis · AMIX · Industrial Applications And Services
Autonomix Medical's Q1 FY2027 10-Q discloses a new Nasdaq rule requiring a $5 million minimum Market Value of Listed Securities, which could trigger immediate delisting without a cure period if the company falls below that threshold. The rule was stayed on July 29, 2026 pending SEC review, but the risk remains. The company also updated its cash runway: current resources, including the $2.6 million warrant inducement from July 2026, fund operations only into but not beyond Q1 2027, and management estimates needing $25-30 million to reach commercialization. With a market cap around $7.3 million, the company is already below the proposed $5 million MVLS threshold, making this a critical listing risk. The going concern warning and material weaknesses in internal controls persist from the prior 10-K.
At the time of this filing, AMIX was trading at $7.41 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $2.44 to $32.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.